RxDoctor Payments Data

Angel Sanchez, MD

Nephrology · Fajardo, PRNPI 1225078462

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,595 of the $4,036 with a category attached, or 64.3%. 15 manufacturers reported payments, led by Merck at 39.4% of the total. Reporting peaked in 2022 at $2,366 and has fallen 88.1% since, to $282 in 2025.

$4,036in general payments, 2019–2025

Across 66 payments — averaging $61.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
  • Johnson & Johnson$1K
  • AstraZeneca$526
  • Boehringer Ingelheim$174
  • Bayer Puerto Rico Inc.$126
  • Calliditas Therapeutics US Inc.$79
  • plus $296 from 9 others

What the payments were for

  • Speaking & faculty fees$2,59564%
  • Food & beverage$1,43536%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,036 in reported general payments places this provider in the 80th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$32,079
Medicare patients
41
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol1,005$745,899
KerendiaFinerenone438$336,039
JardianceEmpagliflozin431$310,464
LokelmaSodium Zirconium Cyclosilicate116$111,795
EliquisApixaban54$45,426
Pentoxifylline862$43,105
OzempicSemaglutide40$39,318
SynjardyEmpagliflozin/Metformin Hcl45$30,254
Sevelamer Carbonate140$30,167
XareltoRivaroxaban53$29,143
TradjentaLinagliptin48$26,495
Candesartan Cilexetil331$24,991
Repatha SureclickEvolocumab34$23,283
Xigduo XrDapaglifloz Propaned/Metformin31$20,452
Lanthanum Carbonate37$17,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$526$857,6941,121 claims
Boehringer IngelheimJardiance, Synjardy, Tradjenta, Glyxambi, Trijardy Xr$174$395,823561 claims
BayerKerendia$53$336,039438 claims
Johnson & JohnsonXarelto, Invokana$1,246$41,87969 claims
MerckJanuvia, Janumet$1,590$26,20143 claims
AbbVieSynthroid$25$16,998251 claims
Lilly USA, LLCHumalog$14$7,781103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Fajardo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →